QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
HILDEN, Germany & GERMANTOWN, Md., July 27, 2022--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) instruments designed to drive greater use among customers, particularly those involved in the biopharma industry:
Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?